CN104961707B - Substituted thiazole ketone secretory protease inhibitors and preparation method thereof - Google Patents
Substituted thiazole ketone secretory protease inhibitors and preparation method thereof Download PDFInfo
- Publication number
- CN104961707B CN104961707B CN201510323862.2A CN201510323862A CN104961707B CN 104961707 B CN104961707 B CN 104961707B CN 201510323862 A CN201510323862 A CN 201510323862A CN 104961707 B CN104961707 B CN 104961707B
- Authority
- CN
- China
- Prior art keywords
- group
- cooh
- och
- substituted
- dioch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention relates to substituted thiazole ketone secretory protease inhibitors and preparation method thereof.A kind of new thiazole ketone compounds are specifically provided, general structure is：The thiazole ketone compounds of the present invention have preferable Sap2 Inhibiting enzyme activities, with antifungal activity in nematode and Mice Body, and there is preferably antimycotic drug combination to act on to fluconazole resistant, therefore be combined available for the medicine for preparing anti-fungal infection or with existing antifungal drug.The present invention opens new way to further investigate and developing new antifungal drug.
Description
Technical field
The present invention relates to medical compounds technical field, specifically, it is related to a kind of new substituted thiazole ketone secretion
Type asparaginic acid protease inhibitors --- { 4- oxygen -3- (substitution) phenyl -2- [(substitution) phenylimino] thiazolidine -5- Asias alkene
Base } (substitution) phenyl class compound and its preparation method and application.
Background technology
In recent years, with the extensive use of the treatment means such as antibiotic, tumor chemoradiotherapy and organ transplant, and AIDS
Illness rate drastically rises, and the diseased colonies that the deep fungal infections such as bacterium, aspergillus fumigatus and neogenesis cryptococcus are read in vain significantly increase
Plus.The increase of resistance candida albicans has turned into a major challenge of clinical antifungal therapy, and existing antifungal drug has one
Fixed limitation.At present, antifungal drug is mainly for four kinds of target enzymes：(azole is antimycotic for 14 α of lanosterol-demethylase
Medicine, such as Fluconazole), fungal cell's membrane lipid (polyene antifungal medicine, such as anphotericin), fungal cell wall β -1,3 Portugals
Glycan synzyme (lipopeptid class antifungal drug, such as MFG) and squalene cyclase (Allylamines antifungal drug, such as naphthalene
For sweet smell).But these medicine generally existing narrow antimicrobial spectrums, adverse reaction strong, poor bioavailability, the shortcomings of be also easy to produce drug resistance.
Therefore, find antifungal drug research new strategy and new target spot seems particularly significant.Experimental results demonstrate secreting type asparagus fern ammonia
Pepsin (secreted aspartic protease, Sap) is the pathogenic important virulence factor of Candida albicans, and
Show the good prospect as antimycotic novel targets.Sap2 is it is verified that be such as that itself is thin with various biological function
Born of the same parents provide nutrition, attachment and invasion host cell, the protective barrier for destroying host, infringement host immune stress reaction etc..Sap2
Report has been seen in the crystal complex of peptides and peptidomimetic class, but the research of its micromolecular inhibitor is still at an early stage.
Have not yet to see { 4- oxygen -3- (substitution) phenyl -2- [(substitution) phenylimino] thiazolidine -5- alkenylenes } (substitution)
The synthesis of phenyl class compound and its relevant report of Sap2 Inhibiting enzyme activities and internal antifungal activity.
The content of the invention
The purpose of the present invention is that there is provided a kind of new thiazole ketone compounds and its system for deficiency of the prior art
Preparation Method and purposes.
The invention provides a kind of thiazole ketone compounds, described thiazole ketone compound structure formula is：
Wherein：
R1Group is located at other any positions that link position is removed on A, B ring, can be monosubstituted or many on A, B ring
Substitution, R1Group is selected from hydrogen, hydroxyl, amino, methyl, ethyl, methoxyl group, ethyoxyl, nitro, cyano group, trifluoromethyl or halogen
Deng；Described halogen is F, Cl, Br or I；
R2Other any positions of group removing link position on C rings can be monosubstituted on C rings or takes more
Generation, R2Group is selected from-OCH2COOH、-diOCH2COOH or-OCH2CONHSO2CF3Deng.
Preferably, described R1Group and R2Group is selected from any of following state：
(1)R1Group is H, R2Group is 2-OCH2COOH；
(2)R1Group is 4-Me, R2Group is 2-OCH2COOH；
(3)R1Group is 3-Me, R2Group is 2-OCH2COOH；
(4)R1Group is 2-Me, R2Group is 2-OCH2COOH；
(5)R1Group is 2,4-diMe, R2Group is 2-OCH2COOH；
(6)R1Group is 2,5-diMe, R2Group is 2-OCH2COOH；
(7)R1Group is 4-F, R2Group is 2-OCH2COOH；
(8)R1Group is 3-F, R2Group is 2-OCH2COOH；
(9)R1Group is 2-F, R2Group is 2-OCH2COOH；
(10)R1Group is 4-Cl, R2Group is 2-OCH2COOH；
(11)R1Group is 3-Cl, R2Group is 2-OCH2COOH；
(12)R1Group is 2-Cl, R2Group is 2-OCH2COOH；
(13)R1Group is 4-Br, R2Group is 2-OCH2COOH；
(14)R1Group is 3-Br, R2Group is 2-OCH2COOH；
(15)R1Group is 2-Br, R2Group is 2-OCH2COOH；
(16)R1Group is 4-OMe, R2Group is 2-OCH2COOH；
(17)R1Group is 3-OMe, R2Group is 2-OCH2COOH；
(18)R1Group is 4-OEt, R2Group is 2-OCH2COOH；
(19)R1Group is 3-OEt, R2Group is 2-OCH2COOH；
(20)R1Group is 2-OEt, R2Group is 2-OCH2COOH；
(21)R1Group is 3,4-diMe, R2Group is 2-OCH2COOH；
(22)R1Group is H, R2Group is 4-OCH2COOH；
(23)R1Group is H, R2Group is 3-OCH2COOH；
(24)R1Group is H, R2Group is 3,4-diOCH2COOH；
(25)R1Group is H, R2Group is 2,4-diOCH2COOH；
(26)R1Group is 4-Me, R2Group is 4-OCH2COOH；
(27)R1Group is 4-Me, R2Group is 3-OCH2COOH；
(28)R1Group is 4-Me, R2Group is 3,4-diOCH2COOH；
(29)R1Group is 4-Me, R2Group is 2,4-diOCH2COOH；
(30)R1Group is 4-OEt, R2Group is 4-OCH2COOH；
(31)R1Group is 4-OEt, R2Group is 3-OCH2COOH；
(32)R1Group is 4-OEt, R2Group is 3,4-diOCH2COOH；
(33)R1Group is 4-OEt, R2Group is 2,4-diOCH2COOH；
(34)R1Group is 3,4-diMe, R2Group is 3,4-diOCH2COOH；
(35)R1Group is 3,4-diMe, R2Group is 2,4-diOCH2COOH；
(36)R1Group is 2,5-diMe, R2Group is 3,4-diOCH2COOH；
(37)R1Group is 2,5-diMe, R2Group is 2,4-diOCH2COOH；
(38)R1Group is 4-F, R2Group is 3,4-diOCH2COOH；
(39)R1Group is 4-F, R2Group is 2,4-diOCH2COOH；
(40)R1Group is 4-Cl, R2Group is 3,4-diOCH2COOH；
(41)R1Group is 4-Cl, R2Group is 2,4-diOCH2COOH；
(42)R1Group is 4-Br, R2Group is 3,4-diOCH2COOH；
(43)R1Group is 4-Br, R2Group is 2,4-diOCH2COOH；
(44)R1Group is 4-OMe, R2Group is 3,4-diOCH2COOH；
(45)R1Group is 4-OMe, R2Group is 2,4-diOCH2COOH；
The chemical constitution of above-mentioned part preferred compound and1H-NMR and MS data are shown in Table 1.
The chemical constitution of the part preferred compound of table 1. and1H-NMR and MS data
It is highly preferred that described R1Group is 4-Me, described R2Group is 2,4-diOCH2COOH。
Present invention also offers the preparation method of described thiazole ketone compounds, comprise the following steps：
(1) 1,3- bis- (substitution) phenylthiourea is prepared
(substitution) aniline and carbon disulfide, triethanolamine and sulphur powder are in water, and return stirring reaction, generation 1,3- bis- (takes
Generation) phenylthiourea；
(2) 3- (substitution) phenyl -2- [(substitution) phenylimino] thiazolidin-4-one is prepared
1,3- bis- (substitution) phenylthiourea, anhydrous sodium acetate and the ethyl chloroacetate heating reflux reaction in absolute ethyl alcohol,
Ethyl alcohol recrystallization obtains 3- (substitution) phenyl -2- [(substitution) phenylimino] thiazolidin-4-one；
(3) 5- [(substitution of 2- ethyls) benzene alkenylene] -3- [(substitution) phenyl] -2- [(substitution) phenyl is prepared
Imino group] thiazolidin-4-one
3- (substitution) phenyl -2- [(substitution) phenylimino] thiazolidin-4-one, (substitution of 2- ethyls) benzaldehyde
With piperidines in absolute ethyl alcohol, 60 DEG C of stirring reactions obtain 5- [(substitution of 2- ethyls) benzene alkenylene] -3- and [(taken
Generation) phenyl] -2- [(substitution) phenylimino] thiazolidin-4-one；
(4) described thiazole ketone compounds are prepared
5- [(substitution of 2- ethyls) benzene alkenylene] -3- [(substitution) phenyl] -2- [(substitution) phenylimino]
Thiazolidin-4-one and LiOHH2O is in THF, MeOH and H2O in the mixed solvent, is stirred at room temperature reaction, obtains described thiazole
Ketone compounds：5- [(substitution of 2- Oxoacetic Acids) benzene alkenylene] -3- [(substitution) phenyl] -2- [(substitution) phenylimino] thiophene
Oxazolidine -4- ketone；
Wherein, described (substitution) aniline structure formula is：
Described 1,3- bis- (substitution) phenylthiourea structural formula is：
Described 3- (substitution) phenyl -2- [(substitution) phenylimino] thiazolidin-4-one structural formula is：
[(substitution) phenyl is sub- by described 5- [(substitution of 2- ethyls) benzene alkenylene] -3- [(substitution) phenyl] -2-
Amino] thiazolidin-4-one structural formula is：
The synthetic reaction formula of described thiazole ketone compounds is as follows：
Present invention also offers the pharmaceutically acceptable salt class of described thiazole ketone compounds.
Preferably, described salt is organic alkali salt or inorganic base salts；Described organic base is (but being not limited only to) methylamine
Or ethamine etc., described inorganic base is (but being not limited only to) potassium hydroxide, sodium hydroxide, potassium carbonate or sodium carbonate etc..
Present invention also offers a kind of pharmaceutical composition, described pharmaceutical composition contains the described thiophene of therapeutically effective amount
Sulfinpyrazone compound or described salt, and surplus pharmaceutically acceptable carrier.
Present invention also offers the purposes of described thiazole ketone compounds or described salt, secretion is suppressed for preparing
The medicine of type aspartic protease.
It is antimycotic for preparing present invention also offers the purposes of described thiazole ketone compounds or described salt
Medicine.
As the preference of the present invention, described fungi is Candida albicans.
The invention has the advantages that：The present invention has obtained new by structure-based virtual screening and further structure optimization
The thiazole ketone compounds of type：{ 4- oxygen -3- (substitution) phenyl -2- [(substitution) phenylimino] thiazolidine -5- alkenylenes } (takes
Generation) phenyl class compound, and confirm that it has and read bacterium Sap2 Inhibiting enzyme activities and internal antifungal activity in vain, and to fluconazole resistant
Bacterium has preferable antimycotic drug combination effect, therefore resists available for the medicine for preparing treatment anti-fungal infection, or with existing
Bacterium drug combination.The present invention opens new approach to further investigate and developing new antifungal drug.
Brief description of the drawings
Fig. 1 (A) Sap2 hydrolyzes substrate principle；(B) FRET-pair absorbs and excites wave spectrum.
Fig. 2 before purification after Sap2 SDS-PAGE.M roads：Labelled protein；1 road：Non- inducible protein；2 roads：Inducible protein；3
Road：Purification of recombinant proteins.
The dialogue of compound 29 reads the Kaplan-Meier survivorship curves that bacterium SC5314 infects nematode in Fig. 3 tables 1.
The dialogue of compound 29 reads the Kaplan-Meier survivorship curves of bacterium SC5314 infecting mouses in Fig. 4 tables 1.
Compound 29 is given birth to the Kaplan-Meier of the infecting mouse of fluconazole resistant clinical strain 0304103 in Fig. 5 tables 1
Deposit curve.
Embodiment
The embodiment that the present invention is provided is elaborated below in conjunction with the accompanying drawings.
Embodiment 1：Prepare 1,3- rhenocure CAs (II, R1=H) preparation
Weigh aniline (2.33g, 25mmol, 2equiv), carbon disulfide (1.24g, 16.25mmol, 2equiv), three ethanol
Amine (2.5mL) and sulphur powder (100mg) are stirred at reflux reaction 6h in 50mL water.Reaction solution is cooled to room temperature, there is white precipitate analysis
Go out.Filtering, and washed with cold water, obtain white solid 1.46g, yield：51%.1H-NMR(300MHz,DMSO-d6)δ:9.78
(s,2H,NH),7.47(m,4H,Ar-H),7.32(m,4H,Ar-H),7.11(m,2H,Ar-H).ESI-MS(m/z):229.28
[M+1].
Embodiment 2：3- phenyl -2- (phenylimino) thiazolidin-4-ones (III, R1=H) preparation
Weigh 1,3- rhenocure CAs (1.14g, 4.0mmol, 1equiv), anhydrous sodium acetate (1.64g, 20.0mmol,
5equiv), 0.85mL ethyl chloroacetates (0.98g, 8.0mmol, 2equiv) are in 20mL absolute ethyl alcohols, 60 DEG C of stirrings of mixture
React 6h.Reaction solution is cooled to room temperature, there is Precipitation.Filtering precipitate, and being washed with ethanol, with re-crystallizing in ethyl acetate,
Obtain orange solids 0.68g, yield：64%, without being further purified, it is directly used in next step reaction.1H-NMR(300MHz,
DMSO-d6)δ:7.47-7.59 (m, 2H), 7.37-7.46 (m, 3H), 7.25-7.36 (m, 2H), 7.08 (t, 1H, J=
7.8Hz),6.81-6.92(m,2H),4.15(s,2H).ESI-MS(m/z):269.35[M+1].
Embodiment 3：2- (2- { [4- oxygen -3- phenyl -2- (phenylimino) thiazolidine -5- alkenylenes] methyl } phenoxy group) second
Acetoacetic ester (IV, R1=H) preparation
Weigh 3- phenyl -2- (phenylimino) thiazolidin-4-one (0.3g, 1.12mmol, 1equiv), 2- formoxyl benzene oxygen
Base ethyl acetate (0.28g, 1.35mmol, 1.2equiv), piperidines (0.095g, 1.12mmol, 1equiv) is in 5mL absolute ethyl alcohols
In, 60 DEG C of stirring reaction 8h of mixture.Combiflash companion purifies (PE-EtOAc, 5:1) faint yellow solid 0.48g, is obtained, is received
Rate：95%.1H-NMR(300MHz,DMSO-d6)δ:8.07(s,1H),7.44-7.62(m,5H),7.30-7.43(m,4H),
7.02-7.22 (m, 3H), 6.90-7.01 (m, 2H), 4.94 (s, 2H), 4.16 (dd, 2H, J=7.06,14.02Hz), 1.20
(t, 3H, J=7.31Hz) .ESI-MS (m/z):459.40[M+1].
Embodiment 4：2- (2- { [4- oxygen -3- phenyl -2- (phenylimino) thiazolidine -5- alkenylenes] methyl } phenoxy group) second
Acid (V, R1=H) preparation (compound 1 in table 1)
Weigh 2- (2- { [4- oxygen -3- phenyl -2- (phenylimino) thiazolidine -5- alkenylenes] methyl } phenoxy group) acetic acid second
Ester (0.1g, 0.22mmol, 1equiv) and LiOHH2O (0.014g, 0.33mmol, 1.5equiv) is in 5mL mixed solvents
(THF:MeOH:H2O=3:2:1) in, reaction 3h is stirred at room temperature.Evaporated under reduced pressure solvent, adds water (20mL), 1M HCl regulations pH
To 2.0-3.0, there is precipitation to generate.Filtering precipitation, is washed with cold water, obtains faint yellow solid 62mg, yield：66%, m.p.：
249-251℃。1H-NMR(500MHz,DMSO-d6)δ:13.25(br s,1H),8.10(s,1H),7.30-7.62(m,9H),
7.16 (t, 1H, J=7.42Hz), 7.08 (t, 1H, J=7.62Hz), 7.02 (d, 1H, J=8.42Hz), 6.97 (d, 2H, J=
7.22Hz),4.81(s,2H).13C-NMR(75MHz,DMSO-d6)δ:172.22,167.90,158.84,152.93,150.23,
137.31,134.03,131.74(2C),131.35(2C),131.03,130.85(2C),130.41,127.46,127.06,
124.50,123.69,123.11(2C),120.45,114.97,67.35.HRESI-MS[M+1]:431.1063.
Agents useful for same is that commercially available analysis is pure in embodiment.
Compound 2-48 repeats the step in embodiment 1-4, just using different substituted aniline as initiation material in table 1
Different substituted thiazole ketone compounds, are further illustrated by taking compound 2-6 as an example needed for synthesizing.
Compound 2 in table：Initiation material is 4- methylanilines, by above-mentioned reaction, obtains 2- (2- { [4- oxygen -3- (4- first
Phenyl) -2- (4- tolylimmos) thiazolidine -5- alkenylenes] methyl } phenoxy group) acetic acid (compound 2).
Compound 3 in table：Initiation material is 3- methylanilines, by above-mentioned reaction, obtains 2- (2- { [4- oxygen -3- (3- first
Phenyl) -2- (3- tolylimmos) thiazolidine -5- alkenylenes] methyl } phenoxy group) acetic acid (compound 3).
Compound 4 in table：Initiation material is 2-aminotoluene, by above-mentioned reaction, obtains 2- (2- { [4- oxygen -3- (2- first
Phenyl) -2- (2- tolylimmos) thiazolidine -5- alkenylenes] methyl } phenoxy group) acetic acid (compound 4).
Compound 5 in table：Initiation material is 2,4- dimethylanilines, by above-mentioned reaction, obtains 2- (2- { [4- oxygen -3-
(2,4- xylyls) -2- (2,4- xylyls imino group) thiazolidine -5- alkenylenes] methyl } phenoxy group) acetic acid (compound
5)。
Compound 6 in table：Initiation material is 2,5- dimethylanilines, by above-mentioned reaction, obtains 2- (2- { [4- oxygen -3-
(2,5- xylyls) -2- (2,5- xylyls imino group) thiazolidine -5- alkenylenes] methyl } phenoxy group) acetic acid (compound
6)。
Embodiment 5：{ 4- oxygen -3- (substitution) phenyl -2- [(substitution) phenylimino] thiazolidine -5- Asias that the present invention is synthesized
Alkenyl } (substitution) phenyl class compound Sap2 Inhibiting enzyme activities
(1) general principle
This experiment is based on fluorescence radiation method and determines enzymatic activity, and Sap2 being capable of specific for hydrolysis amino acid peptide bond, such peptide fragment
(H2N-Dabcyl-Arg-Lys-Pro-Ala-Leu-Phe-┆-Phe-Arg-Leu-Glu(EDANS)–Arg-CO2H) two phenylpropyl alcohols
Propylhomoserin is connected peptide bond can be by its specific for hydrolysis.Above-mentioned peptide fragment is FRET-pair-labeled substrates
The substrate of (fluorescence resonance energy transfer) FRET base group modification, substrate
One end by Dabcyl (4,4-dimethyl aminoazobenzene-4 '-carboxylic acid) modify, the other end by
EDANS (5- [(2-aminoethyl) amino] naphthalene-1-sulfonic acid) base group modification, when EDANS groups
After being excited, its emission band can be fully absorbed by Dabcyl groups, therefore, when two groups are located on same substrate,
Fluorescence radiation is absorbed；When substrate is hydrolyzed, the hydrolysis substrate with EDANS groups will send very strong fluorescence.
(2) test material
Substrate：H2N-Dabcyl-Arg-Lys-Pro-Ala-Leu-Phe-Phe-Arg-Leu-Glu(EDANS)-Arg-
CO2H (customization of gill biochemical industry company), Sap2 enzymes (Nanjing bronze object Bioisystech Co., Ltd prokaryotic expression).
(3) other materials
Sodium citrate buffer solution (50mM, pH 4.5,50mM containing NaCl, autogamy)；
Positive drug：Pepstatin A(Sigma)；
DMSO：Sigma；
Black does not combine flat 96 orifice plate：Corning, model 3650.
(4) instrument
Instrument：The multi-function microplate readers of Bioteck Synergy 2, Gen5 operation softwares.
(5) sample is configured
Substrate is configured to the stand-by solution of 18.75 μM of concentration with DMSO；Positive drug PepA DMSO dissolve, and are configured to series
Concentration：10 μM~0.001nM；Other testing samples DMSO dissolves, and is configured to series concentration：100 μM~0.01 μM.Experiment is single
Position：Totally 200 μ L, the μ L substrates (DMSO solution) of+5 μ L inhibitor (DMSO solution) of+5 μ L enzymes of 185 μ L buffer solutions+5, each concentration list
Position is duplicate hole.The Sap2 enzymes sodium citrate buffer solutions of pH 4.5 dilute 10 times, room temperature activation 2h.It is dense by hydrolyzing 18.75 μM
The substrate of degree, enzyme is diluted to 100units/min concentration, and now fluorescence intensity is with time linear growth, the dilution of enzyme
It is stand-by.
(6) test method
A) 185 μ L sodium citrate buffer solutions, 5 μ L Sap2 enzymes, 5 μ L inhibitor are sequentially added into the orifice plate of black 96, sets double
Multiple holes, PepA does positive control, and the DMSO that inhibitor is not added does blank.Solution system is sufficiently mixed vibration, 30 DEG C of incubations
30min。
B) 18.75 μM of μ L of substrate 5 are added, vibration plate is well mixed, as time point, compound fluorescence is determined per 10min
Luminous (λ ex=340/30nm, λ em=485/20nm).
C) according to the increase degree of unit interval fluorescence radiation, the inhibiting rate % of inhibitor under each concentration is calculated.
D) inhibiting rate of each concentration and the log values of sample concentration are carried out nonlinear fitting, obtains activity and dosage
Dependence, IC is directly obtained by software50Value.Software Graphpad prism 5.0, fitting module：log(inhibitor)
Vs response--varible slop, 0 and 100% are set to by matched curve bottom and top.
(7) experimental result
The part thiazole ketone compounds of the present invention are shown in Table 2 to Sap2 Inhibiting enzyme activity.
Inhibiting enzyme activity of the thiazole ketone compounds of the present invention of table 2. to Sap2
Embodiment 6：2,2'- [(4- { [4- oxygen -3- (4- tolyls) -2- (4- Tolyliminos) thiazoles that the present invention is synthesized
Alkane -5- alkenylenes] methyl -1,3- phenyl) two (oxygen)] and oxalic acid (compound 29 in table 1) nematode body in antifungal activity
(1) test material
1) bacterial strain
Read bacterium SC5314 (C.albicansSC5314) in vain.
2) nematode
Caenorhabditis elegans glp-4；sek-1(C.elegans glp-4；sek-1nematodes).
3) culture medium
BHI culture mediums, NGM culture mediums, LB culture mediums, YPD culture mediums, M9 buffer solutions, nematode lysate.
4) medicine
Positive drug Fluconazole (fluconazole), PBS makees negative control.
(2) test method
1) culture of nematode
15 DEG C of cultures of NGM culture mediums containing Escherichia coli.Escherichia coli：The 37 DEG C of cultures of LB fluid nutrient mediums.
2) synchronization of nematode
Nematode cultivates 5-6d to ovum is educated in 15 DEG C of insulating boxs, clean with M9 wash buffers, adds lysate nematode, shakes
Worm's ovum is collected after swinging；Hatch 24h in M9 buffer solutions, obtain L1 phase larvas, be then transferred to 25 DEG C of culture 3d on NGM culture mediums, obtain
L4 phase adults.
3) bacterium nematode infections model is read in vain
A) be grown on YPD Agr culture medium it is white read bacterium picking single bacterium and fall within 2mL YPD fluid nutrient mediums, 30 DEG C
Overnight incubation.Next day, 100 μ L bacterium solutions (μ g/mL containing kanamycins 45) on BHI agar mediums are taken, release square bacterial plaque, 30
DEG C culture 20h.
B) synchronized Caenorhabditis elegans glp-4；Sek-1 adults are clean with M9 wash buffers, and 400~500 are done
Net nematode be placed in it is white read in the square bacterial plaque of bacterium, 25 DEG C of culture 4h (the reserved not microbiological contamination nematode as blank control).
C) nematode is placed in 15mL conical pipes is carefully rinsed with the sterile M9 buffer solutions of 6mL, is rinsed four times altogether.
D) in 12 hole tissue culturing plates (Corning), the 2mL culture mediums (μ containing 80%M9,20%BHI, 45 is added per hole
G/mL kanamycins).Afterwards, 30 nematodes are put into per hole to be cultivated.
E) every group of drug concentration gradient is 4,8,16,32 μ g/mL, and sets up not medicine feeding hole control.Every kind of processing is all provided with 3 holes
Parallel control.Culture plate is cultivated into 5d in 25 DEG C, each hole nematode survival situation is counted per 24h.Living nematode form is in sinusoidal pattern；Extremely
The linear type of nematode form, no wriggling, platinum filament touching is reactionless.
F) nematode viability data are mapped using Kaplan-Meier methods, and log-rank, which is examined, carries out statistics credit
Analysis.P<0.05 thinks statistically significant, mapping analysis software Graphpad prism 5.0.
(3) experimental result
According to Sap2 Inhibiting enzyme activity results, Caenorhabditis elegans (Caenorhabditis is tested to compound 29
Elegans) antifungal growth activity in fungal infection model.Fluconazole (fluconazole) is used as positive control drug
Dosage is experiment common dose 32 μ g/mL.As a result show, compared with blank control, compound 29 (P=0.0128) dialogue reads bacterium
The nematode of infection shows excellent protective effect (Fig. 3), and the survival rate for obtaining nematode maintains 70%, with positive control drug fluorine
Health azoles has similar action effect in 32 μ g/mL of concentration.
Embodiment 7：2,2'- [(4- { [4- oxygen -3- (4- tolyls) -2- (4- Tolyliminos) thiazoles that the present invention is synthesized
Alkane -5- alkenylenes] methyl -1,3- phenyl) two (oxygen)] and oxalic acid (compound 29 in table 1) Mice Body in antifungal activity
(1) test material
1) experimental animal
ICR mouse (Shanghai Slac Experimental Animal Co., Ltd.), cleaning grade, 18~20g of body weight, female.License
Demonstrate,prove number：SCXK (Shanghai) 2012-002.Animal for research foundation《The feeding management of experimental animal and the regulation used》.
2) experimental strain
White to read bacterium SC5314 (C.albicans SC5314), the court new drug research center is provided；Fluconazole resistant reads bacterium in vain
Clinical strain 0304103, by Changhai, hospital provides, through morphology and biochemical identification.
3) culture medium
YPD (yeast extract peptone dextrose culture medium, yeast peptonedextrose) culture medium.
4) medicine
Positive drug Fluconazole is dissolved in physiological saline；Physiological saline makees negative control；Test medicine is dissolved in physiological saline.
5) laboratory apparatus
Full temperature shaken cultivation case (Jiangsu granary instrument factory), high speed freezing centrifuge (Heraeus).
(2) test method
1) foundation of systemic fungal infection model
A) bacterium SC5314 or clinical strain 0304103 will be read in 30 DEG C of shaking tables in vain, YPD medium cultures, the bacterium after activation
Liquid is inoculated into 1% in fresh YPD culture mediums, i.e. add 10 μ L bacterium solutions in 1mL YPD, 16h is cultivated in 10mL test tubes.
B) by the cultured bacterium solution 1000g force centrifugation 5min in exponential phase, 0.9% physiological saline repeats 3
Secondary washing, discards supernatant, and blood counting chamber is counted, and bacterium solution is diluted into 5 × 10 with physiological saline6CFU/mL injection is dense
Degree.
C) ICR mouse are grouped at random, every group 10, each experimental group is independently repeated twice.Diluted by tail vein injection
Good reads bacterium bacterium solution 0.1mL/10g in vain so that ICR mouse generation system fungal infections.
2) by group being administered and observe life span
A) ICR mouse are grouped (read bacterium SC5314 infection in vain) at random：Fungal infection model group (blank control group), Fluconazole
(0.5mg/kg) alone treatment group, test compound (2mg/kg) alone treatment group.
ICR mouse are grouped (fluconazole resistant clinical strain 0304103 infects) at random：A groups are model control groups
(Blank), not treated after infection resistance candida albicans；B groups are intraperitoneal injection Fluconazole 0.5mg/kg；C groups are left intraperitoneal injection
Fluconazole 0.5mg/kg, the right dosage 2mg/kg of intraperitoneal injection compound 29 (drug combination group).
B) ICR mouse systems are read after bacterium infection 2h in vain, and each group mouse difference intraperitoneal injection 0.2mL/ only, is often preordained
When injection once, successive administration 7d.Mouse survival situation is observed, the daily dead number of record each group is calculated every group small daily
The survival rate of mouse, observation to 20d or Fluconazole is administered alone group all death.
C) Survival data is mapped using Kaplan-Meier methods, and log-rank, which is examined, carries out statistical analysis.P<
0.05 thinks statistically significant, mapping analysis software Graphpad prism 5.0.
(3) experimental result
As a result Fig. 4 is seen, the mouse that dialogue reads bacterium SC5314 infection sets up test model, in seven days of administration, blank pair
All dead according to group, compound 29 has the effect for necessarily delaying mouse dead in table 1, there is significant difference (P=0.0128),
But contrast its therapeutic action with Fluconazole independent medication and also have certain gap.
As a result Fig. 5 is seen, Fluconazole clinical drug-resistant reads the infecting mouse of bacterium 0304103 and set up test model, as a result shows, give in vain
Medicine seven days, blank control group is all dead within the 8th day, and Fluconazole survival rate 50%, drug combination group survival rate reaches 100%；
The all death in the 14th day of Fluconazole group, now drug combination group survival rate reaches 50%.A groups mean survival time is 6.6d；B groups
Mean survival time is 9.5d；C groups mean survival time is 14.7d.Drug combination group and Fluconazole independent medication comparing difference
Substantially, C groups are compared Log-rank inspections, P with A groups<0.0001；C groups are compared Log-rank inspections, P=0.0026 with B groups；B groups
Compared Log-rank inspections with A groups, P=0.0198 is statistically significant.Drug combination is to fluconazole resistant infecting mouse
With preferable protective effect, the death rate of mouse can be effectively reduced, strengthens and effect is resisted to fluconazole resistant.
It is above-mentioned test result indicates that, the thiazole ketone compounds that synthesize of the present invention have preferable Sap2 Inhibiting enzyme activities, and
With preferable antifungal activity in vivo, it is the Sap2 of a class new construction type to illustrate the thiazole ketone compounds of the invention synthesized
Inhibitor and Antifungal Compounds, available for prepare treatment anti-fungal infection medicine, to fluconazole resistant have compared with
Good antimycotic drug combination prospect.The present invention opens new approach to further investigate and developing new antifungal drug.
Described above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
Member, on the premise of the inventive method is not departed from, can also make some improvement and supplement, and these are improved and supplement also should be regarded as
Protection scope of the present invention.
Claims (9)
1. a kind of thiazole ketone compounds, it is characterised in that described thiazole ketone compound structure formula is：
Described R1Group and R2Group is selected from any of following state：
(1)R1Group is 3-Me, R2Group is 2-OCH2COOH；
(2)R1Group is 2,4-diMe, R2Group is 2-OCH2COOH；
(3)R1Group is 2,5-diMe, R2Group is 2-OCH2COOH；
(4)R1Group is 3-F, R2Group is 2-OCH2COOH；
(5)R1Group is 2-F, R2Group is 2-OCH2COOH；
(6)R1Group is 4-Cl, R2Group is 2-OCH2COOH；
(7)R1Group is 3-Cl, R2Group is 2-OCH2COOH；
(8)R1Group is 2-Cl, R2Group is 2-OCH2COOH；
(9)R1Group is 4-Br, R2Group is 2-OCH2COOH；
(10)R1Group is 3-Br, R2Group is 2-OCH2COOH；
(11)R1Group is 2-Br, R2Group is 2-OCH2COOH；
(12)R1Group is 4-OMe, R2Group is 2-OCH2COOH；
(13)R1Group is 3-OMe, R2Group is 2-OCH2COOH；
(14)R1Group is 4-OEt, R2Group is 2-OCH2COOH；
(15)R1Group is 3-OEt, R2Group is 2-OCH2COOH；
(16)R1Group is 2-OEt, R2Group is 2-OCH2COOH；
(17)R1Group is H, R2Group is 3,4-diOCH2COOH；
(18)R1Group is 4-Me, R2Group is 3-OCH2COOH；
(19)R1Group is 4-Me, R2Group is 3,4-diOCH2COOH；
(20)R1Group is 4-Me, R2Group is 2,4-diOCH2COOH；
(21)R1Group is 4-OEt, R2Group is 4-OCH2COOH；
(22)R1Group is 4-OEt, R2Group is 3-OCH2COOH；
(23)R1Group is 4-OEt, R2Group is 3,4-diOCH2COOH；
(24)R1Group is 4-OEt, R2Group is 2,4-diOCH2COOH；
(25)R1Group is 3,4-diMe, R2Group is 3,4-diOCH2COOH；
(26)R1Group is 3,4-diMe, R2Group is 2,4-diOCH2COOH；
(27)R1Group is 2,5-diMe, R2Group is 3,4-diOCH2COOH；
(28)R1Group is 2,5-diMe, R2Group is 2,4-diOCH2COOH；
(29)R1Group is 4-F, R2Group is 3,4-diOCH2COOH；
(30)R1Group is 4-F, R2Group is 2,4-diOCH2COOH；
(31)R1Group is 4-Cl, R2Group is 3,4-diOCH2COOH；
(32)R1Group is 4-Cl, R2Group is 2,4-diOCH2COOH；
(33)R1Group is 4-Br, R2Group is 3,4-diOCH2COOH；
(34)R1Group is 4-Br, R2Group is 2,4-diOCH2COOH；
(35)R1Group is 4-OMe, R2Group is 3,4-diOCH2COOH；
(36)R1Group is 4-OMe, R2Group is 2,4-diOCH2COOH。
2. thiazole ketone compounds according to claim 1, it is characterised in that described R1Group is 4-Me, described R2
Group is 2,4-diOCH2COOH。
3. the preparation method of the thiazole ketone compounds described in claim 1 or 2, it is characterised in that comprise the following steps：
(1) 1,3- di-substituted-phenyl thiocarbamides are prepared
Substituted aniline and carbon disulfide, triethanolamine and sulphur powder are in water, and return stirring reaction generates 1,3- di-substituted-phenyl sulphur
Urea；
(2) 3- substituted-phenyls -2- (substitution phenylimino) thiazolidin-4-one is prepared
1,3- di-substituted-phenyl thiocarbamide, anhydrous sodium acetate and the ethyl chloroacetate heating reflux reaction in absolute ethyl alcohol, ethanol weight
Crystallization obtains 3- substituted-phenyls -2- (substitution phenylimino) thiazolidin-4-one；
(3) 5- (2- ethyl substituted benzenes alkenylene) -3- (substituted-phenyl) -2- (substituted-phenyl imino group) thiazole is prepared
Alkane -4- ketone
3- substituted-phenyls -2- (substitution phenylimino) thiazolidin-4-one, 2- ethyls substituted benzaldehyde and piperidines are in nothing
In water-ethanol, 60 DEG C of stirring reactions obtain 5- (2- ethyl substituted benzenes alkenylene) -3- (substituted-phenyl) -2- (substitutions
Phenylimino) thiazolidin-4-one；
(4) described thiazole ketone compounds are prepared
5- (2- ethyl substituted benzenes alkenylene) -3- (substituted-phenyl) -2- (substituted-phenyl imino group) thiazolidin-4-one
And LiOHH2O is in THF, MeOH and H2O in the mixed solvent, is stirred at room temperature reaction, obtains described thiazole ketone compounds：
5- (2- Oxoacetic Acid substituted benzenes alkenylene) -3- (substituted-phenyl) -2- (substituted-phenyl imino group) thiazolidin-4-one；
Wherein, described substituted aniline structural formula is：
Described 1,3- di-substituted-phenyl thiocarbamide structural formulas are：
Described 3- substituted-phenyls -2- (substitution phenylimino) thiazolidin-4-one structural formula is：
4. the pharmaceutically acceptable salt class of the thiazole ketone compounds described in claim 1.
5. salt according to claim 4, it is characterised in that described salt is organic alkali salt or inorganic base salts；It is described
Organic base be methylamine or ethamine, described inorganic base is potassium hydroxide, sodium hydroxide, potassium carbonate or sodium carbonate.
6. a kind of pharmaceutical composition, it is characterised in that described pharmaceutical composition contains described in the claim 1 of therapeutically effective amount
Thiazole ketone compounds or claim 4 described in salt, and surplus pharmaceutically acceptable carrier.
7. the purposes of the salt described in thiazole ketone compounds or claim 4 described in claim 1, it is characterised in that use
In the medicine for preparing suppression secretory protease.
8. the purposes of the salt described in thiazole ketone compounds or claim 4 described in claim 1, it is characterised in that use
In preparing antimycotic medicine.
9. purposes according to claim 8, it is characterised in that described fungi is Candida albicans.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510323862.2A CN104961707B (en) | 2015-06-12 | 2015-06-12 | Substituted thiazole ketone secretory protease inhibitors and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510323862.2A CN104961707B (en) | 2015-06-12 | 2015-06-12 | Substituted thiazole ketone secretory protease inhibitors and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104961707A CN104961707A (en) | 2015-10-07 |
| CN104961707B true CN104961707B (en) | 2017-07-28 |
Family
ID=54215831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510323862.2A Active CN104961707B (en) | 2015-06-12 | 2015-06-12 | Substituted thiazole ketone secretory protease inhibitors and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104961707B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112575055A (en) * | 2020-12-21 | 2021-03-30 | 广西壮族自治区兽医研究所 | Method for rapidly detecting virulence of bovine-derived Shigella by using defective caenorhabditis elegans |
| CN113200866A (en) * | 2021-03-29 | 2021-08-03 | 龙曦宁（上海）医药科技有限公司 | Synthetic method of diafenthiuron impurity D |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040167192A1 (en) * | 2003-01-16 | 2004-08-26 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
| CN1657529A (en) * | 2004-02-20 | 2005-08-24 | 中国科学院上海药物研究所 | 2-substituted imine thia zlidine derivative its preparation technology and medicinal composition |
| CN102285936A (en) * | 2011-06-24 | 2011-12-21 | 南京工业大学 | 4-thiazolidone carboxilic acid derivatives and preparation method and use thereof |
-
2015
- 2015-06-12 CN CN201510323862.2A patent/CN104961707B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040167192A1 (en) * | 2003-01-16 | 2004-08-26 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
| CN1657529A (en) * | 2004-02-20 | 2005-08-24 | 中国科学院上海药物研究所 | 2-substituted imine thia zlidine derivative its preparation technology and medicinal composition |
| CN102285936A (en) * | 2011-06-24 | 2011-12-21 | 南京工业大学 | 4-thiazolidone carboxilic acid derivatives and preparation method and use thereof |
Non-Patent Citations (14)
| Title |
|---|
| "105341-05-7";Registry;《STN on the web》;19861122 * |
| "302933-62-6";Registry;《STN on the web》;20001115 * |
| "302933-69-3";Registry;《STN on the web》;20001115 * |
| "353472-43-2";Registry;《STN on the web》;20010829 * |
| "354544-60-8";Registry;《STN on the web》;20010904 * |
| "445251-30-9";Registry;《STN on the web》;20020828 * |
| "692767-81-0";Registry;《STN on the web》;20040614 * |
| 4-噻唑酮羧酸衍生物的合成;朱明莉 等;《南京工业大学学报(自然科学版)》;20090731;第31卷(第4期);第79-83页，摘要，第79页左栏，第80页图1，1.3实验方法，引证文献14-Thiazolidinone－A biologically active scaffold，Amit Verma et al，European Journal of Medicinal Chemistry，第43卷，第897-905页，公开日期为2007年8月6日，3.6 Antibacterialactivity、3.9 Antifungalactivity * |
| Bin Pan et al.Thiazolidione derivatives as novel antibiofi * |
| Design, synthesis, and antibiofilm activity of 2-arylimino-3-aryl-thiazolidine- 4-ones;Pan Bin et al;《Bioorganic & Medicinal Chemistry Letters》;20100307;第20卷(第8期);第2461-2464页，Scheme 3 * |
| Greener approach to the synthesis of 4-thiazolidinone derivatives using phase transfer catalysts under microwave irradiation;Naeem, Muhammad et al;《Journal of the Chemical Society of Pakistan》;20091231;第31卷(第4期);第633-637页 * |
| lm agents: Design, synthesis, biological evaluation, and structure－activity relationships.《European Journal of Medicinal Chemistry》.2010,第46卷第819-824页，Scheme 3. * |
| Thiazolidione derivatives targeting the histidine kinase YycG are effective against both planktonic and biofilm-associated Staphylococcus epidermidis;Huang Ren-zheng et al;《Acta Pharmacologica Sinica》;20120109;第33卷(第3期);第418-425页，第419页化合物H2-10 * |
| 抗真菌药物靶标及其抑制剂的研究进展;徐波 等;《药学实践杂志》;20130925;第31卷(第5期);第321-325、379页，第324-325页4分泌型天冬氨酸蛋白酶 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104961707A (en) | 2015-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113181339A (en) | Medicinal application of aldehyde compound | |
| Marc et al. | New N-(oxazolylmethyl)-thiazolidinedione active against Candida albicans biofilm: potential Als proteins inhibitors | |
| CN104961707B (en) | Substituted thiazole ketone secretory protease inhibitors and preparation method thereof | |
| Matio Kemkuignou et al. | Macrooxazoles A–D, new 2, 5-disubstituted oxazole-4-carboxylic acid derivatives from the plant pathogenic fungus Phoma macrostoma | |
| Le et al. | Chemical composition and biological activities of metabolites from the marine fungi Penicillium sp. isolated from sediments of Co To Island, Vietnam | |
| Mahmood et al. | Ethyl 3-oxo-2-(2, 5-dioxopyrrolidin-3-yl) butanoate derivatives: anthelmintic and cytotoxic potentials, antimicrobial, and docking studies | |
| Sugawara et al. | Creation of customized bioactivity within a 14-membered macrolide scaffold: design, synthesis, and biological evaluation using a family-18 chitinase | |
| CN108558850B (en) | Bactericide containing thiophene ring and stilbene amide, and preparation method and application thereof | |
| Cong et al. | Synthesis and antibacterial activity of analogs of 5-arylidene-3-(4-methylcoumarin-7-yloxyacetylamino)-2-thioxo-1, 3-thiazoli-din-4-one | |
| Tiwari et al. | Synthesis, biological evaluation, molecular docking study and acute oral toxicity study of coupled imidazole-pyrimidine derivatives | |
| Bi et al. | Anti-Vibrio dibutyl phthalate from marine-derived Streptomyces sp. S073 | |
| Zhao et al. | Rational design of N-methylcarbamoylguanidinyl derivatives as highly potent dual-target chitin hydrolase inhibitors for retarding growth of pest insects | |
| CN103965193B (en) | N-(benzene oxyalkyl) imidazo [1,2-a] pyridine-3-amides and preparation method thereof | |
| CN103193770B (en) | Replace benzothiazoles antifungal compound and preparation method thereof and application | |
| CN105566262A (en) | Benzofuran-7-alkylamine compounds and applications thereof | |
| CN102285936A (en) | 4-thiazolidone carboxilic acid derivatives and preparation method and use thereof | |
| CN109608447B (en) | Benzothiazole diazole derivative and preparation method and application thereof | |
| Lai et al. | Design, synthesis and antibacterial evaluation of a novel class of tetrahydrobenzothiophene derivatives | |
| CN104974142A (en) | Substituted triaminotriazine secreting-type aspartic protease inhibitor and preparation method thereof | |
| Xu et al. | Design, Synthesis, Fungicidal and Insecticidal Activities of Novel Diamide Compounds Combining Pyrazolyl and Polyfluoro-Substituted Phenyl into Alanine or 2-Aminobutyric Acid Skeletons | |
| JP2005500289A (en) | Lactone formulations and methods of use | |
| CN114621214B (en) | Antibacterial Schiff base N-acylate, and preparation method and application thereof | |
| SU1156597A3 (en) | Method of obtaining 3-(n-alkylsulfonylphenyl) oxazolidinone derivatives or their pharmaceutically acceptable acid-additive salts | |
| Zhu et al. | Synthesis and Biological Evaluation of Dipeptide-Based Stilbene Derivatives Bearing a Biheterocyclic Moiety as Potential Fungicides | |
| CN107898784A (en) | Application of the eltrombopag olamine monoethanolamine in Killing Mycobacterium Tuberculosis infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |